Literature DB >> 2277589

Evidence for participation of the macrophage in Shiga-like toxin II-induced lethality in mice.

T J Barrett1, M E Potter, N A Strockbine.   

Abstract

Seven strains of inbred mice were compared for their susceptibility to the lethal effects of Shiga-like toxin II (SLT II). A/J mice, which are unable to produce the C5 component of complement, did not differ from C5 normal mice in susceptibility to SLT II. CBA/NJ mice (hemizygous for X-linked immunodeficiency) did not differ from the B-cell sufficient CBA/J strain. C3H/HeJ mice, defective in macrophage response to lipopolysaccharide (Lpsd), showed a consistently and significantly longer mean time to death than did the normally responsive C3H/HeN strain. C57BL/10ScN mice, which also carry the Lpsd allele, showed a similar but smaller difference in mean time to death compared with the C57BL/10SnJ strain. Production of tumor necrosis factor could be induced in vitro by SLT II treatment of C3H/HeN, but not C3H/HeJ macrophages. These results imply that antibody and complement production do not modulate SLT II lethality in mice, but that the macrophage may contribute to SLT II-induced injury.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2277589     DOI: 10.1016/0882-4010(90)90083-3

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  15 in total

1.  Strong association between shiga toxin-producing Escherichia coli O157 and virulence genes stx2 and eae as possible explanation for predominance of serogroup O157 in patients with haemolytic uraemic syndrome.

Authors:  D Werber; A Fruth; U Buchholz; R Prager; M H Kramer; A Ammon; H Tschäpe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-12       Impact factor: 3.267

2.  Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.

Authors:  M S Palermo; M F Alves Rosa; N Van Rooijen; M A Isturiz
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

3.  Role of nitric oxide in the enhancement of pentylenetetrazole-induced seizures caused by Shigella dysenteriae.

Authors:  J Balter-Seri; Y Yuhas; A Weizman; Y Nofech-Mozes; E Kaminsky; S Ashkenazi
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

4.  Immune response to verotoxin 1 and 2 in children with Escherichia coli O157:H7 hemorrhagic colitis and classic hemolytic uremic syndrome.

Authors:  F Proulx; J P Turgeon; G Delage; H Lior; L Lafleur; L Chicoine
Journal:  Can J Infect Dis       Date:  1995-05

5.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

6.  Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro.

Authors:  C B Louise; T G Obrig
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

7.  Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.

Authors:  V L Tesh; J A Burris; J W Owens; V M Gordon; E A Wadolkowski; A D O'Brien; J E Samuel
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

8.  A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome.

Authors:  Y Harel; M Silva; B Giroir; A Weinberg; T B Cleary; B Beutler
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages.

Authors:  V L Tesh; B Ramegowda; J E Samuel
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines.

Authors:  B Ramegowda; V L Tesh
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.